Adeno-associated Virus as a Mammalian DNA Vector
Open accessThe DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
In the nearly five decades since its accidental discovery, adeno-associated virus (AAV) has emerged as a highly versatile vector system for both research and clinical applications. A broad range of natural serotypes, as well as an increasing number of capsid variants, has combined to produce a repertoire of vectors with different tissue tropisms, immunogenic profiles and transduction efficiencies. The story of AAV is one of continued progress and surprising discoveries in a viral system that, at first glance, is deceptively simple. This apparent simplicity has enabled the advancement of AAV into the clinic, where despite some challenges it has provided hope for patients and a promising new tool for physicians. Although a great deal of work remains to be done, both in studying the basic biology of AAV and in optimizing its clinical application, AAV vectors are currently the safest and most efficient platform for gene transfer in mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696 · cited 2×
“…have taken a more holistic directed evolution approach by generating libraries of novel AAV sequences either by random mutagenesis (100 – 102) or shuf fl ing of capsid sequences across multiple serotypes followed by selection on either a target cell population (99, 103 – 107) or in vivo (108 – 113).”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“The prevalence of NAbs in children is lower, ranging from 13 to 25% (216, 219).”
BackgroundSelf-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 1×
“Whatever the exact mechanism of endosomal escape, AAV does enter the cytoplasm where a portion of the infecting virions is subjected to phosphorylation and targeting for proteasome-mediated degradation (119, 142–144) The use of proteasomeinhibiting drugs (121, 140, 141) and surface tyrosine mutants (123, 135, 141) bot…”
BackgroundMcCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547 · cited 4×
“…could be intentionally induced using a plasmid containing a wild-type ITR sequence, transgenic DNA ( ≤ 2.3 kb) and a truncated ITR in which the trs is deleted and therefore, is de fi cient for Rep-induced resolution of the typical double-stranded AAV genome intermediate (Figure 2) (161, 162, 177).”
BackgroundInfluentialSelf-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 2×
“AAV trafficking post-entry has been associated with a broad range of organelles from both the endosomal (88, 116, 121) and caveolin (120, 125) pathways, and appears to be influenced by a wide range of factors such as initial route of entry and initial infecting dose (126, 127).”
BackgroundSelf-citationDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 2×
“Although mutation of the PLA2 domain is highly detrimental to infection and results in the perinuclear accumulation of virus, it also appears by itself to be insufficient to facilitate endosomal escape of the 3-MDa parvovirus capsid (108, 110, 112, 138, 139).”
BackgroundSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 2×
“In fact, in the absence of normal checkpoint functions, such as in p53-de fi cient cells or human embryonic stem cells, it has been reported that AAV vector transduction results in cell death (148, 151, 163).”
BackgroundResultNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470 · cited 1×
“The low efficiency with which AAVs transduce professional antigen-presenting cells such as macrophages and dendritic cells (67, 204, 205) was suspected as the reason behind their relatively low immunogenicity.”
BackgroundSamulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Self-citationSelection and evaluation of clinically relevant AAV variants in a xenograft liver model
Lisowski, L., Dane, A. P., Chu, K., Zhang, Y., Cunningham, S. C., Wilson, E. M., Nygaard, S., Grompe, M., Alexander, I. E., & Kay, M. A. (2014) · Nature · doi:10.1038/nature12875 · Cited by 450 · cited 1×
“…have taken a more holistic directed evolution approach by generating libraries of novel AAV sequences either by random mutagenesis (100 – 102) or shuf fl ing of capsid sequences across multiple serotypes followed by selection on either a target cell population (99, 103 – 107) or in vivo (108 – 113).”
BackgroundIntegration of Adeno-Associated Virus (AAV) and Recombinant AAV Vectors
McCarty, D. M., Young, S. M., & Samulski, R. J. (2004) · Annual Review of Genetics · doi:10.1146/annurev.genet.37.110801.143717 · Cited by 450
Self-citationHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Self-citationDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
AAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392 · cited 2×
“In addition, Mre11, a key sensor of damaged DNA normally considered part of the HR pathway, in conjunction with Nbs1 and Rad50, also appears to inhibit AAV transduction (145, 146, 160).”
BackgroundA viral assembly factor promotes AAV2 capsid formation in the nucleolus
Sonntag, F., Schmidt, K., & Kleinschmidt, J. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001673107 · Cited by 392
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
Identification of PDGFR as a receptor for AAV-5 transduction
Pasquale, G. D., Davidson, B. L., Stein, C. S., Martins, I., Scudiero, D., Monks, A., & Chiorini, J. A. (2003) · Nature Medicine · doi:10.1038/nm929 · Cited by 355
Girod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 1×
“The VP1 Nterminus is critical for infection and contains a phospholipase A2 domain (94, 137) along with a broad range of signaling motifs (100, 136, 137) including several nuclear localization sites (103, 104, 135, 137).”
BackgroundJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330 · cited 1×
“Although 11 additional AAV serotypes have been explored for gene therapy purposes, minimal cross-reactivity of NAbs has been demonstrated among these types in animals (218, 220 – 223).”
BackgroundSamulski, R. J., Srivastava, A., Berns, K. I., & Muzyczka, N. (1983) · Cell · doi:10.1016/0092-8674(83)90342-2 · Cited by 297
Self-citationMingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295
Douar, A.-M., Poulard, K., Stockholm, D., & Danos, O. (2001) · Journal of Virology · doi:10.1128/jvi.75.4.1824-1833.2001 · Cited by 282 · cited 4×
“However, a growing body of work suggests that this is only one of several entry pathways that different AAVs can use with evidence implicating the caveolin pathway (119, 120), as well as the clathrin-independent carrier mediated/glycosylphosphatidylinositol-anchoredprotein-enriched endosomal compartment-associated (CL…”
BackgroundInfluentialWobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273 · cited 1×
“Variations within these loop regions are also thought to eliminate antibody recognition of serotypes AAV1 and AAV3–9 (41, 42).”
BackgroundScallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266
Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Self-citationJanson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255
Ellis, B. L., Hirsch, M. L., Barker, J. C., Connelly, J. P., Steininger, R. J., & Porteus, M. H. (2013) · Virology Journal · doi:10.1186/1743-422x-10-74 · Cited by 252
Self-citationHepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.609-614.2005 · Cited by 246
Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 1×
“However, a growing body of work suggests that this is only one of several entry pathways that different AAVs can use with evidence implicating the caveolin pathway (119, 120), as well as the clathrin-independent carrier mediated/glycosylphosphatidylinositol-anchoredprotein-enriched endosomal compartment-associated (CL…”
BackgroundSubcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Virus-mediated killing of cells that lack p53 activity
Raj, K., Ogston, P., & Beard, P. (2001) · Nature · doi:10.1038/35091082 · Cited by 207
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4
Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J. A., & Agbandje-McKenna, M. (2006) · Journal of Virology · doi:10.1128/jvi.01536-06 · Cited by 205
Warrington, K. H., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., & Muzyczka, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6595-6609.2004 · Cited by 205
Bleker, S., Sonntag, F., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2528-2540.2005 · Cited by 200 · cited 1×
“This pore is the site of genome packaging (16) and is thought to be necessary for the externalization of N-terminal minor capsid protein motifs necessary for AAV infection (16, 17).”
BackgroundKronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198 · cited 1×
“This pore is the site of genome packaging (16) and is thought to be necessary for the externalization of N-terminal minor capsid protein motifs necessary for AAV infection (16, 17).”
BackgroundNakai, H., Storm, T. A., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9451-9463.2000 · Cited by 194 · cited 2×
“Following the generation of a duplexed DNA molecule, the vector genome primarily remains episomal and circularizes via intra-and inter-molecular ITR linkages shortly after infection (134 – 136, 142, 151).”
BackgroundThe AAV9 receptor and its modification to improve in vivo lung gene transfer in mice
Bell, C. L., Vandenberghe, L. H., Bell, P., Limberis, M. P., Gao, G.-P., Van Vliet, K., Agbandje-McKenna, M., & Wilson, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57367 · Cited by 190
Large‐scale molecular characterization of adeno‐associated virus vector integration in mouse liver
Nakai, H., Wu, X., Fuess, S., Storm, T. A., Munroe, D., Montini, E., Burgess, S. M., Grompe, M., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.6.3606-3614.2005 · Cited by 190 · cited 5×
“Consistent with these in vivo data, elegant work performed in the mouse liver demonstrated that Artemis and DNA-PKcs process the AAV ITRs and promote the circularization/ concatamerization of vector genomes, which is also supported by other reports (62, 136, 137, 153 – 156).”
BackgroundResultInfluentialGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185
Self-citationAsokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Self-citationGene therapy for lipoprotein lipase deficiency
Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178
Grieger, J. C., Snowdy, S., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.02723-05 · Cited by 172 · cited 1×
“…have taken a more holistic directed evolution approach by generating libraries of novel AAV sequences either by random mutagenesis (100 – 102) or shuf fl ing of capsid sequences across multiple serotypes followed by selection on either a target cell population (99, 103 – 107) or in vivo (108 – 113).”
BackgroundSelf-citationPEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 1×
“The prevalence of NAbs in children is lower, ranging from 13 to 25% (216, 219).”
BackgroundCarpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165
RPE65: Role in the Visual Cycle, Human Retinal Disease, and Gene Therapy
Cai, X., Conley, S. M., & Naash, M. I. (2009) · Ophthalmic Genetics · doi:10.1080/13816810802626399 · Cited by 162 · cited 1×
“The therapy was based on the subretinal delivery of an rAAV2 vector carrying a functional copy of RPE65 , which restores the conversion of all-trans -retinal to 11-cis -ret- inal, and would allow for the repeated signaling from photoreceptors (198).”
MethodFactors that bind to adeno-associated virus terminal repeats
Im, D. S., & Muzyczka, N. (1989) · Journal of Virology · doi:10.1128/jvi.63.7.3095-3104.1989 · Cited by 157 · cited 1×
“The N-termini of the larger Rep proteins contain a DNA-binding domain, as well as strand-speci fi c endonuclease activity, necessary for initiating replication during virion production and site-speci fi c integration (46, 53 – 56).”
BackgroundHost Cell DNA Repair Pathways in Adeno-Associated Viral Genome Processing
Choi, V. W., McCarty, D. M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00841-06 · Cited by 144
Self-citationHorowitz, E. D., Rahman, K. S., Bower, B. D., Dismuke, D. J., Falvo, M. R., Griffith, J. D., Harvey, S. C., & Asokan, A. (2013) · Journal of Virology · doi:10.1128/jvi.03017-12 · Cited by 139 · cited 1×
“The AAV ITRs can assume a T-shaped structure (43) and exist in two conformations termed “ fl ip ” or “ fl op ” and generated during the rolling hairpin mechanism of replication (44).”
BackgroundInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136
Self-citationCombinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136 · cited 1×
“Others have taken a more holistic directed evolution approach by generating libraries of novel AAV sequences either by random mutagenesis (100 – 102) or shuf fl ing of capsid sequences across multiple serotypes followed by selection on either a target cell population (99, 103 – 107) or in vivo (108…”
BackgroundAdeno‐associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo†‡
Paulk, N. K., Wursthorn, K., Wang, Z., Finegold, M. J., Kay, M. A., & Grompe, M. (2010) · Hepatology · doi:10.1002/hep.23481 · Cited by 135 · cited 4×
“Despite this academic understanding of HR, AAV gene editing has corrected a murine model of hereditary tyrosinemia type 1 (174).”
BackgroundInfluentialDesign and Packaging of Adeno-Associated Virus Gene Targeting Vectors
Hirata, R. K., & Russell, D. W. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4612-4620.2000 · Cited by 133 · cited 4×
“For instance, exit from the cell cycle in vivo increases transduction, whereas an earlier report demonstrated that cells in S-phase are transduced much better (200-fold increase) compared with nondividing cells (142, 146, 158).”
BackgroundMethodInfluentialThe Mre11/Rad50/Nbs1 complex limits adeno-associated virus transduction and replication
Schwartz, R. A., Palacios, J. A., Cassell, G. D., Adam, S., Giacca, M., & Weitzman, M. D. (2007) · Journal of Virology · doi:10.1128/jvi.01523-07 · Cited by 130
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
Capsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127 · cited 1×
“The three-fold axis is characterized by prominent spike-like protrusions and contains the known receptor binding sites (12, 13) as well as many of the identified antibody recognition sites (14, 15).”
BackgroundSelf-citationStructure of Adeno-Associated Virus Serotype 5
Walters, R. W., Agbandje-McKenna, M., Bowman, V. D., Moninger, T. O., Olson, N. H., Seiler, M., Chiorini, J. A., Baker, T. S., & Zabner, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3361-3371.2004 · Cited by 114
Characterization of adenovirus-associated virus-induced polypeptides in KB cells
Buller, R. M., & Rose, J. A. (1978) · Journal of Virology · doi:10.1128/jvi.25.1.331-338.1978 · Cited by 111 · cited 1×
“The VPs of all AAVs share a common C-terminus, with VP1 (87 kDa), and VP2 (73 kDa) each having additional N-terminal sequences when compared with VP3 (62 kDa) (18, 19).”
BackgroundHeparin binding induces conformational changes in Adeno-associated virus serotype 2
Levy, H. C., Bowman, V. D., Govindasamy, L., McKenna, R., Nash, K., Warrington, K., Chen, W., Muzyczka, N., Yan, X., Baker, T. S., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2008.12.002 · Cited by 110
Nam, H.-J., Gurda, B. L., McKenna, R., Potter, M., Byrne, B., Salganik, M., Muzyczka, N., & Agbandje-McKenna, M. (2011) · Journal of Virology · doi:10.1128/jvi.05305-11 · Cited by 108 · cited 2×
“An acidic environment has been shown to lead to structural transitions in the AAV capsid (85, 134), which activate an autocatalytic protease activity within the capsid (86, 134–136) and prime the capsid for externalization of the VP1 N-terminal domains (88, 135).”
BackgroundSelf-citationProperties of the Adeno-Associated Virus Assembly-Activating Protein
Naumer, M., Sonntag, F., Schmidt, K., Nieto, K., Panke, C., Davey, N. E., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of Virology · doi:10.1128/jvi.01675-12 · Cited by 97
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
Self-citationCervelli, T., Palacios, J. A., Zentilin, L., Mano, M., Schwartz, R. A., Weitzman, M. D., & Giacca, M. (2008) · Journal of Cell Science · doi:10.1242/jcs.003632 · Cited by 84 · cited 2×
“Single-strand DNA vector genomes are uncoated within the nucleus and form discrete foci whose abundance directly correlates to the transduction efficiency (128, 147).”
BackgroundGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80 · cited 1×
“While LCA can be caused by mutation in several genes, it consistently results in the early onset of retinal degeneration and is the most prevalent cause of childhood blindness (197).”
BackgroundLovric, J., Mano, M., Zentilin, L., Eulalio, A., Zacchigna, S., & Giacca, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.144 · Cited by 77 · cited 5×
“For instance, exit from the cell cycle in vivo increases transduction, whereas an earlier report demonstrated that cells in S-phase are transduced much better (200-fold increase) compared with nondividing cells (142, 146, 158).”
BackgroundInfluentialOversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62
Self-citationAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61
Self-citationBarker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
Viral Single-Strand DNA Induces p53-Dependent Apoptosis in Human Embryonic Stem Cells
Hirsch, M. L., Fagan, B. M., Dumitru, R., Bower, J. J., Yadav, S., Porteus, M. H., Pevny, L. H., & Samulski, R. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027520 · Cited by 53
Self-citation
Research works printed but not linked: 150
- Atchison RW Casto BC Hammon WM. 1965. Adenovirus-associated defective virus particles. Science 149: 754–756. [PubMed][CrossRef] · DOI · Paper page
- Rose JA Berns KI Hoggan MD Koczot FJ. 1969. Evidence for a single-stranded adenovirus-associated virus genome: formation of a DNA density hybrid on release of viral DNA. Proc Natl Acad Sci USA 64: 863–869. [PubMed][CrossRef] · DOI · Paper page
- Zhong L Zhou X Li Y Qing K Xiao X Samulski RJ Srivastava A. 2008. Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo : mechanism of transduction. Mol Ther 16: 290–295. [PubMed][CrossRef] · DOI · Paper page
- Kotin RM Siniscalco M Samulski RJ Zhu XD Hunter L Laughlin CA McLaughlin S Muzyczka N Rocchi M Berns KI. 1990. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211–2215. [PubMed][CrossRef] · DOI · Paper page
- Samulski RJ Zhu X Xiao X Brook JD Housman DE Epstein N Hunter LA. 1991. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10: 3941–3950. [PubMed] · DOI · Paper page
- Linden RM Ward P Giraud C Winocour E Berns KI. 1996. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93: 11288–11294. [PubMed][CrossRef] · DOI · Paper page
- Mitchell AM Nicolson SC Warischalk JK Samulski RJ. 2010. AAV's anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther 10: 319–340. [PubMed][CrossRef] · DOI · Paper page
- Young SM Mccarty DM Degtyareva N Samulski RJ. 2000. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 74: 3953–3966. [PubMed][CrossRef] · DOI · Paper page
- Opie SR Warrington KH Agbandje-McKenna M Zolotukhin S Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77: 6995–7006. [PubMed][CrossRef] · DOI · Paper page
- Gurda BL Raupp C Popa-Wagner R Naumer M Olson NH Ng R McKenna R Baker TS Kleinschmidt JA Agbandje-McKenna M. 2012. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J Virol 86: 7739–7751. [PubMed][CrossRef] · DOI · Paper page
- Muzyczka N. 1992. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 158: 97–129. [PubMed][CrossRef] · DOI · Paper page
- Rolling F Samulski RJ. 1995. AAV as a viral vector for human gene therapy. Generation of recombinant virus. Mol Biotechnol 3: 9–15. [PubMed][CrossRef] · DOI
- DiMattia M Govindasamy L Levy HC Gurda-Whitaker B Kalina A Kohlbrenner E Chiorini JA McKenna R Muzyczka N Zolotukhin S Agbandje-McKenna M. 2005. Production purification crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 917–921. [PubMed][CrossRef] · DOI · Paper page
- Xie Q Ongley HM Hare J Chapman MS. 2008. Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallogr Sect F Struct Biol Cryst Commun 64: 1074–1078. [PubMed][CrossRef] · DOI
- Padron E Bowman V Kaludov N Govindasamy L Levy H Nick P McKenna R Muzyczka N Chiorini JA Baker TS Agbandje-McKenna M. 2005. Structure of adeno-associated virus type 4. J Virol 79: 5047–5058. [PubMed][CrossRef] · DOI · Paper page
- Kaludov N Padron E Govindasamy L McKenna R Chiorini JA Agbandje-McKenna M. 2003. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 4. Virology 306: 1–6. [PubMed][CrossRef] · DOI
- Nam H-J Lane MD Padron E Gurda B McKenna R Kohlbrenner E Aslanidi G Byrne B Muzyczka N Zolotukhin S Agbandje-McKenna M. 2007. Structure of adeno-associated virus serotype 8 a gene therapy vector. J Virol 81: 12260–12271. [PubMed][CrossRef] · DOI · Paper page
- Lerch TF Xie Q Ongley HM Hare J Chapman MS. 2009. Twinned crystals of adeno-associated virus serotype 3b prove suitable for structural studies. Acta Crystallogr Sect F Struct Biol Cryst Commun 65: 177–183. [PubMed][CrossRef] · DOI
- Mitchell M Nam H-J Carter A McCall A Rence C Bennett A Gurda B McKenna R Porter M Sakai Y Byrne BJ Muzyczka N Aslanidi G Zolotukhin S Agbandje-McKenna M. 2009. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 9. Acta Crystallogr Sect F Struct Biol Cryst Commun 65: 715–718. [PubMed][CrossRef] · DOI · Paper page
- Miller EB Gurda-Whitaker B Govindasamy L McKenna R Zolotukhin S Muzyczka N Agbandje-McKenna M. 2006. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr Sect F Struct Biol Cryst Commun 62: 1271–1274. [PubMed][CrossRef] · DOI · Paper page
- Quesada O Gurda B Govindasamy L McKenna R Kohlbrenner E Aslanidi G Zolotukhin S Muzyczka N Agbandje-McKenna M. 2007. Production purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 1073–1076. [PubMed][CrossRef] · DOI · Paper page
- Lane MD Nam H-J Padron E Gurda-Whitaker B Kohlbrenner E Aslanidi G Byrne B McKenna R Muzyczka N Zolotukhin S Agbandje-McKenna M. 2005. Production purification crystallization and preliminary X-ray analysis of adeno-associated virus serotype 8. Acta Crystallogr Sect F Struct Biol Cryst Commun 61: 558–561. [PubMed][CrossRef] · DOI
- O'Donnell J Taylor KA Chapman MS. 2009. Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology 385: 434–443. [PubMed][CrossRef] · DOI · Paper page
- Lerch TF Xie Q Chapman MS. 2010. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 403: 26–36. [PubMed][CrossRef] · DOI · Paper page
- Ng R Govindasamy L Gurda BL McKenna R Kozyreva OG Samulski RJ Parent KN Baker TS Agbandje-McKenna M. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 84: 12945–12957. [PubMed][CrossRef] · DOI · Paper page
- Rabinowitz JE Bowles DE Faust SM Ledford JG Cunningham SE Samulski RJ. 2004. Cross-dressing the virion : the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 78: 4421–4432. [PubMed][CrossRef] · DOI · Paper page
- Cavalier-Smith T. 1974. Palindromic base sequences and replication of eukaryote chromosome ends. Nature 250: 467–470. [PubMed][CrossRef] · DOI · Paper page
- Snyder RO Im DS Ni T Xiao X Samulski RJ Muzyczka N. 1993. Features of the adeno-associated virus origin involved in substrate recognition by the viral Rep protein. J Virol 67: 6096–6104. [PubMed] · DOI · Paper page
- Chiorini JA Wiener SM Owens RA Kyöstiö SR Kotin RM Safer B. 1994. Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats. J Virol 68: 7448–7457. [PubMed] · DOI · Paper page
- Mccarty DM Pereira DJ Zolotukhin I Zhou X Ryan JH Muzyczka N. 1994. Identification of linear DNA sequences that specifically bind the adeno-associated virus Rep protein. J Virol 68: 4988–4997. [PubMed] · DOI · Paper page
- Mccarty DM Ryan JH Zolotukhin S Zhou X Muzyczka N. 1994. Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol 68: 4998–5006. [PubMed] · DOI · Paper page
- Weitzman MD Kyöstiö SR Kotin RM Owens RA. 1994. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 91: 5808–5812. [PubMed][CrossRef] · DOI · Paper page
- Straus SE Sebring ED Rose JA. 1976. Concatemers of alternating plus and minus strands are intermediates in adenovirus-associated virus DNA synthesis. Proc Natl Acad Sci USA 73: 742–746. [PubMed][CrossRef] · DOI · Paper page
- Lusby E Bohenzky R Berns KI. 1981. Inverted terminal repetition in adeno-associated virus DNA: independence of the orientation at either end of the genome. J Virol 37: 1083–1086. [PubMed] · DOI · Paper page
- Snyder RO Im DS Muzyczka N. 1990. Evidence for covalent attachment of the adeno-associated virus (AAV) rep protein to the ends of the AAV genome. J Virol 64: 6204–6213. [PubMed] · DOI · Paper page
- Im DS Muzyczka N. 1990. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 61: 447–457. [PubMed][CrossRef] · DOI · Paper page
- Owens RA Weitzman MD Kyöstiö SR Carter BJ. 1993. Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins. J Virol 67: 997–1005. [PubMed] · DOI · Paper page
- Chiorini JA Weitzman MD Owens RA Urcelay E Safer B Kotin RM. 1994. Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli. J Virol 68: 797–804. [PubMed] · DOI · Paper page
- Brister JR Muzyczka N. 1999. Rep-mediated nicking of the adeno-associated virus origin requires two biochemical activities DNA helicase activity and transesterification. J Virol 73: 9325–9336. [PubMed] · DOI · Paper page
- Wonderling RS Kyöstiö SR Owens RA. 1995. A maltose-binding protein/adeno-associated virus Rep68 fusion protein has DNA–RNA helicase and ATPase activities. J Virol 69: 3542–3548. [PubMed] · DOI · Paper page
- Snyder RO Samulski RJ Muzyczka N. 1990. In vitro resolution of covalently joined AAV chromosome ends. Cell 60: 105–113. [PubMed][CrossRef] · DOI · Paper page
- Hermonat PL Labow MA Wright R Berns KI Muzyczka N. 1984. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 51: 329–339. [PubMed] · DOI · Paper page
- Samulski RJ Chang LS Shenk T. 1989. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63: 3822–3828. [PubMed] · DOI · Paper page
- Ferrari FK Xiao X McCarty D Samulski RJ. 1997. New developments in the generation of Ad-free high-titer rAAV gene therapy vectors. Nat Med 3: 1295–1297. [PubMed][CrossRef] · DOI
- Grieger JC Samulski RJ. 2012. Adeno-associated virus vectorology manufacturing and clinical applications. Meth Enzymol 507: 229–254. [PubMed][CrossRef] · DOI · Paper page
- Fisher KJ Gao GP Weitzman MD DeMatteo R Burda JF Wilson JM. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 70: 520–532. [PubMed] · DOI · Paper page
- Wu Z Miller E Agbandje-McKenna M Samulski RJ. 2006. Alpha2 3 and alpha2 6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80: 9093–9103. [PubMed][CrossRef] · DOI · Paper page
- Summerford C Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438–1445. [PubMed] · DOI · Paper page
- Kaludov N Brown KE Walters RW Zabner J Chiorini JA. 2001. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75: 6884–6893. [PubMed][CrossRef] · DOI · Paper page
- Walters RW Yi SM Keshavjee S Brown KE Welsh MJ Chiorini JA Zabner J. 2001. Binding of adeno-associated virus type 5 to 2 3-linked sialic acid is required for gene transfer. J Biol Chem 276: 20610–20616. [PubMed][CrossRef] · DOI · Paper page
- Shen S Bryant KD Brown SM Randell SH Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286: 13532–13540. [PubMed][CrossRef] · DOI · Paper page
- Müller OJ Leuchs B Pleger ST Grimm D Franz W-M Katus HA Kleinschmidt JA. 2006. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70: 70–78. [PubMed][CrossRef] · DOI · Paper page
- Asokan A Conway JC Phillips JL Li C Hegge J Sinnott R Yadav S DiPrimio N Nam H-J Agbandje-McKenna M McPhee S Wolff J Samulski RJ. 2010. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol 28: 79–82. [PubMed][CrossRef] · DOI · Paper page
- Shen S Horowitz ED Troupes AN Brown SM Pulicherla N Samulski RJ Agbandje-McKenna M Asokan A. 2013. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem 288: 28814–28823. [PubMed][CrossRef] · DOI · Paper page
- Yang Q Mamounas M Yu G Kennedy S Leaker B Merson J Wong-Staal F Yu M Barber JR. 1998. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Human Gene Ther 9: 1929–1937. [PubMed][CrossRef] · DOI · Paper page
- Grifman M Trepel M Speece P Gilbert LB Arap W Pasqualini R Weitzman MD. 2001. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3: 964–975. [PubMed][CrossRef] · DOI · Paper page
- Loiler SA Conlon TJ Song S Tang Q Warrington KH Agarwal A Kapturczak M Li C Ricordi C Atkinson MA Muzyczka N Flotte TR. 2003. Targeting recombinant adeno-associated virus vectors to enhance gene transfer to pancreatic islets and liver. Gene Ther 10: 1551–1558. [PubMed][CrossRef] · DOI
- Shi W Arnold GS Bartlett JS. 2001. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12: 1697–1711. [PubMed][CrossRef] · DOI · Paper page
- Müller OJ Kaul F Weitzman MD Pasqualini R Arap W Kleinschmidt JA Trepel M. 2003. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21: 1040–1046. [PubMed][CrossRef] · DOI · Paper page
- Judd J Wei F Nguyen PQ Tartaglia LJ Agbandje-McKenna M Silberg JJ Suh J. 2012. Random insertion of mCherry into VP3 domain of adeno-associated virus yields fluorescent capsids with no loss of infectivity. Mol Ther Nucleic Acids 1: e54. [PubMed][CrossRef] · DOI · Paper page
- Salganik M Venkatakrishnan B Bennett A Lins B Yarbrough J Muzyczka N Agbandje-McKenna M McKenna R. 2012. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J Virol 86: 11877–11885. [PubMed][CrossRef] · DOI · Paper page
- Münch RC Janicki H Völker I Rasbach A Hallek M Büning H Buchholz CJ. 2013. Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer. Mol Ther 21: 109–118. [PubMed][CrossRef] · DOI · Paper page
- Sonntag F Bleker S Leuchs B Fischer R Kleinschmidt JA. 2006. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J Virol 80: 11040–11054. [PubMed][CrossRef] · DOI · Paper page
- White AF Mazur M Sorscher EJ Zinn KR Ponnazhagan S. 2008. Genetic modification of adeno-associated viral vector type 2 capsid enhances gene transfer efficiency in polarized human airway epithelial cells. Hum Gene Ther 19: 1407–1414. [PubMed][CrossRef] · DOI
- Nicklin SA Buening H Dishart KL de Alwis M Girod A Hacker U Thrasher AJ Ali RR Hallek M Baker AH. 2001. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 4: 174–181. [PubMed][CrossRef] · DOI · Paper page
- White SJ Nicklin SA Büning H Brosnan MJ Leike K Papadakis ED Hallek M Baker AH. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109: 513–519. [PubMed][CrossRef] · DOI · Paper page
- Work LM Büning H Hunt E Nicklin SA Denby L Britton N Leike K Odenthal M Drebber U Hallek M Baker AH. 2006. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13: 683–693. [PubMed][CrossRef] · DOI · Paper page
- Yu C-Y Yuan Z Cao Z Wang B Qiao C Li J Xiao X. 2009. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther 16: 953–962. [PubMed][CrossRef] · DOI · Paper page
- Perabo L Büning H Kofler DM Ried MU Girod A Wendtner CM Enssle J Hallek M. 2003. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 8: 151–157. [PubMed][CrossRef] · DOI · Paper page
- Waterkamp DA Müller OJ Ying Y Trepel M Kleinschmidt JA. 2006. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med 8: 1307–1319. [PubMed][CrossRef] · DOI · Paper page
- Michelfelder S Lee M-K deLima-Hahn E Wilmes T Kaul F Müller O Kleinschmidt JA Trepel M. 2007. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol 35: 1766–1776. [PubMed][CrossRef] · DOI
- Michelfelder S Kohlschütter J Skorupa A Pfennings S Müller O Kleinschmidt JA Trepel M. 2009. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS ONE 4: e5122. [PubMed][CrossRef] · DOI · Paper page
- Popa-Wagner R Porwal M Kann M Reuss M Weimer M Florin L Kleinschmidt JA. 2012. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol 86: 9163–9174. [PubMed][CrossRef] · DOI · Paper page
- Johnson JS Li C DiPrimio N Weinberg MS McCown TJ Samulski RJ. 2010. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 84: 8888–8902. [PubMed][CrossRef] · DOI · Paper page
- Maguire CA Gianni D Meijer DH Shaket LA Wakimoto H Rabkin SD Gao G Sena-Esteves M. 2010. Directed evolution of adeno-associated virus for glioma cell transduction. J Neurooncol 96: 337–347. [PubMed][CrossRef] · DOI · Paper page
- Ward P Walsh CE. 2009. Chimeric AAV Cap sequences alter gene transduction. Virology 386: 237–248. [PubMed][CrossRef] · DOI
- Farr GA Zhang L-G Tattersall P. 2005. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc Natl Acad Sci USA 102: 17148–17153. [PubMed][CrossRef] · DOI · Paper page
- Yang L Jiang J Drouin LM Agbandje-McKenna M Chen C Qiao C Pu D Hu X Wang D-Z Li J Xiao X. 2009. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci USA 106: 3946–3951. [PubMed][CrossRef] · DOI · Paper page
- Mani B Baltzer C Valle N Almendral JM Kempf C Ros C. 2006. Low pH-dependent endosomal processing of the incoming parvovirus minute virus of mice virion leads to externalization of the VP1 N-terminal sequence (N-VP1) N-VP2 cleavage and uncoating of the full-length genome. J Virol 80: 1015–1024. [PubMed][CrossRef] · DOI
- Cohen S Marr AK Garcin P Panté N. 2011. Nuclear envelope disruption involving host caspases plays a role in the parvovirus replication cycle. J Virol 85: 4863–4874. [PubMed][CrossRef] · DOI
- Xiao P-J Samulski RJ. 2012. Cytoplasmic trafficking endosomal escape and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 86: 10462–10473. [PubMed][CrossRef] · DOI · Paper page
- Duan D Li Q Kao AW Yue Y Pessin JE Engelhardt JF. 1999. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 73: 10371–10376. [PubMed] · DOI · Paper page
- Uhrig S Coutelle O Wiehe T Perabo L Hallek M Büning H. 2012. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther 19: 210–218. [PubMed][CrossRef] · DOI
- Liu Y Joo K-I Wang P. 2012. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. Gene Ther 20: 308–317. [PubMed][CrossRef] · DOI
- Bantel-Schaal U Braspenning-Wesch I Kartenbeck J. 2009. Adeno-associated virus type 5 exploits two different entry pathways in human embryo fibroblasts. J Gen Virol 90: 317–322. [PubMed][CrossRef] · DOI · Paper page
- Nonnenmacher M Weber T. 2011. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10: 563–576. [PubMed][CrossRef] · DOI · Paper page
- Nicolson SC Samulski RJ. 2014. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 88: 4132–4144. [PubMed][CrossRef] · DOI · Paper page
- Johnson JS Samulski RJ. 2009. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol 83: 2632–2644. [PubMed][CrossRef] · DOI · Paper page
- Salganik M Aydemir F Nam H-J McKenna R Agbandje-McKenna M Muzyczka N. 2014. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol 88: 1071–1079. [PubMed][CrossRef] · DOI · Paper page
- Ding W Zhang LN Yeaman C Engelhardt JF. 2006. rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion. Mol Ther 13: 671–682. [PubMed][CrossRef] · DOI · Paper page
- Hauck B Zhao W High K Xiao W. 2004. Intracellular viral processing not single-stranded DNA accumulation is crucial for recombinant adeno-associated virus transduction. J Virol 78: 13678–13686. [PubMed][CrossRef] · DOI · Paper page
- Hauswirth WW Berns KI. 1979. Adeno-associated virus DNA replication: nonunit-length molecules. Virology 93: 57–68. [PubMed][CrossRef] · DOI
- Ni TH McDonald WF Zolotukhin I Melendy T Waga S Stillman B Muzyczka N. 1998. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol 72: 2777–2787. [PubMed] · DOI · Paper page
- Nash K Chen W McDonald WF Zhou X Muzyczka N. 2007. Purification of host cell enzymes involved in adeno-associated virus DNA replication. J Virol 81: 5777–5787. [PubMed][CrossRef] · DOI · Paper page
- Song S Laipis PJ Berns KI Flotte TR. 2001. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 98: 4084–4088. [PubMed][CrossRef] · DOI · Paper page
- Inagaki K Ma C Storm TA Kay MA Nakai H. 2007. The role of DNA-PKcs and artemis in opening viral DNA hairpin termini in various tissues in mice. J Virol 81: 11304–11321. [PubMed][CrossRef] · DOI · Paper page
- Xiao X Li J Samulski RJ. 1996. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098–8108. [PubMed] · DOI · Paper page
- Sanlioglu S Duan D Engelhardt JF. 1999. Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum Gene Ther 10: 591–602. [PubMed][CrossRef] · DOI · Paper page
- Zentilin L Marcello A Giacca M. 2001. Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 75: 12279–12287. [PubMed][CrossRef] · DOI · Paper page
- Russell DW Alexander IE Miller AD. 1995. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci USA 92: 5719–5723. [PubMed][CrossRef] · DOI · Paper page
- Miller JL Donahue RE Sellers SE Samulski RJ Young NS Nienhuis AW. 1994. Recombinant adeno-associated virus (rAAV)-mediated expression of a human gamma-globin gene in human progenitor-derived erythroid cells. Proc Natl Acad Sci USA 91: 10183–10187. [PubMed][CrossRef] · DOI · Paper page
- Rahman SH Bobis-Wozowicz S Chatterjee D Gellhaus K Pars K Heilbronn R Jacobs R Cathomen T. 2013. The nontoxic cell cycle modulator indirubin augments transduction of adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting. Hum Gene Ther 24: 67–77. [PubMed][CrossRef] · DOI · Paper page
- Winocour E Callaham MF Huberman E. 1988. Perturbation of the cell cycle by adeno-associated virus. Virology 167: 393–399. [PubMed][CrossRef] · DOI
- Fragkos M Beard P. 2011. Mitotic catastrophe occurs in the absence of apoptosis in p53-null cells with a defective G1 checkpoint. PLoS ONE 6: e22946. [PubMed][CrossRef] · DOI
- Fragkos M Jurvansuu J Beard P. 2009. H2AX is required for cell cycle arrest via the p53/p21 pathway. Mol Cell Biol 29: 2828–2840. [PubMed][CrossRef] · DOI · Paper page
- Miao CH Snyder RO Schowalter DB Patijn GA Donahue B Winther B Kay MA. 1998. The kinetics of rAAV integration in the liver. Nat Genet 19: 13–15. [PubMed][CrossRef] · DOI · Paper page
- Yang CC Xiao X Zhu X Ansardi DC Epstein ND Frey MR Matera AG Samulski RJ. 1997. Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro . J Virol 71: 9231–9247. [PubMed] · DOI · Paper page
- Miller DG Trobridge GD Petek LM Jacobs MA Kaul R Russell DW. 2005. Large-scale analysis of adeno-associated virus vector integration sites in normal human cells. J Virol 79: 11434–11442. [PubMed][CrossRef] · DOI · Paper page
- Flotte TR Afione SA Zeitlin PL. 1994. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11: 517–521. [PubMed][CrossRef] · DOI · Paper page
- Xiao X Xiao W Li J Samulski RJ. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J Virol 71: 941–948. [PubMed] · DOI · Paper page
- Hirsch ML Agbandje-McKenna M Samulski RJ. 2010. Little vector big gene transduction : fragmented genome reassembly of adeno-associated virus. Mol Ther 18: 6–8. [PubMed][CrossRef] · DOI · Paper page
- Lai Y Zhao J Yue Y Wasala NB Duan D. 2014. Partial restoration of cardiac function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet 23: 3189–3199. [PubMed][CrossRef] · DOI
- Russell DW Hirata RK. 1998. Human gene targeting by viral vectors. Nat Genet 18: 325–330. [PubMed][CrossRef] · DOI · Paper page
- Smithies O Gregg RG Boggs SS Koralewski MA Kucherlapati RS. 1985. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317: 230–234. [PubMed][CrossRef] · DOI · Paper page
- Thomas KR Capecchi MR. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503–512. [PubMed][CrossRef] · DOI · Paper page
- Russell DW Hirata RK. 2008. Human gene targeting favors insertions over deletions. Hum Gene Ther 19: 907–914. [CrossRef] · DOI
- Vasileva A Linden RM Jessberger R. 2006. Homologous recombination is required for AAV-mediated gene targeting. Nucleic Acids Res 34: 3345–3360. [PubMed][CrossRef] · DOI · Paper page
- Trobridge G Hirata RK Russell DW. 2005. Gene targeting by adeno-associated virus vectors is cell-cycle dependent. Hum Gene Ther 16: 522–526. [PubMed][CrossRef] · DOI
- Petek LM Fleckman P Miller DG. 2010. Efficient KRT14 targeting and functional characterization of transplanted human keratinocytes for the treatment of epidermolysis bullosa simplex. Mol Ther 18: 1624–1632. [PubMed][CrossRef] · DOI
- Paulk NK Wursthorn K Haft A Pelz C Clarke G Newell AH Olson SB Harding CO Finegold MJ Bateman RL Witte JF McClard R Grompe M. 2012. In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice. Mol Ther 20: 1981–1987. [PubMed][CrossRef] · DOI
- Mueller C Flotte TR. 2008. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15: 858–863. [PubMed][CrossRef] · DOI · Paper page
- Rabinowitz JE Rolling F Li C Conrath H Xiao W Xiao X Samulski RJ. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791–801. [PubMed][CrossRef] · DOI · Paper page
- Podsakoff G Wong KK Chatterjee S. 1994. Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 68: 5656–5666. [PubMed] · DOI · Paper page
- Berns KI Pinkerton TC Thomas GF Hoggan MD. 1975. Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68: 556–560. [PubMed][CrossRef] · DOI
- Tenenbaum L Lehtonen E Monahan PE. 2003. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 3: 545–565. [PubMed][CrossRef] · DOI · Paper page
- Testa F Maguire AM Rossi S Pierce EA Melillo P Marshall K Banfi S Surace EM Sun J Acerra C Wright JF Wellman J High KA Auricchio A Bennett J Simonelli F. 2013. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120: 1283–1291. [PubMed][CrossRef] · DOI · Paper page
- Bennett J Ashtari M Wellman J Marshall KA Cyckowski LL Chung DC McCague S Pierce EA Chen Y Bennicelli JL Zhu X Ying G-S Sun J Wright JF Auricchio A Simonelli F Shindler KS Mingozzi F High KA Maguire AM. 2012. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4: 120ra15. [PubMed][CrossRef] · DOI · Paper page
- Hajjar RJ Zsebo K Deckelbaum L Thompson C Rudy J Yaroshinsky A Ly H Kawase Y Wagner K Borow K Jaski B London B Greenberg B Pauly DF Patten R Starling R Mancini D Jessup M. 2008. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 14: 355–367. [PubMed][CrossRef] · DOI · Paper page
- Jacobson SG Cideciyan AV Ratnakaram R Heon E Schwartz SB Roman AJ Peden MC Aleman TS Boye SL Sumaroka A Conlon TJ Calcedo R Pang J-J Erger KE Olivares MB Mullins CL Swider M Kaushal S Feuer WJ Iannaccone A Fishman GA Stone EM Byrne BJ Hauswirth WW. 2012. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 130: 9–24. [PubMed][CrossRef] · DOI · Paper page
- Ross CJD Twisk J Bakker AC Miao F Verbart D Rip J Godbey T Dijkhuizen P Hermens WTJMC Kastelein JJP Kuivenhoven JA Meulenberg JM Hayden MR. 2006. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 17: 487–499. [PubMed][CrossRef] · DOI · Paper page
- Chuah M VandenDriessche T. 2007. Gene therapy for hemophilia “A” and “B”: efficacy safety and immune consequences. Verh K Acad Geneeskd Belg 69: 315–334. [PubMed]
- Chen J Wu Q Yang P Hsu H-C Mountz JD. 2006. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 13: 260–269. [PubMed][CrossRef] · DOI · Paper page
- Li C Hirsch M Asokan A Zeithaml B Ma H Kafri T Samulski RJ. 2007. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo . J Virol 81: 7540–7547. [PubMed][CrossRef] · DOI · Paper page
- Li H Murphy SL Giles-Davis W Edmonson S Xiang Z Li Y Lasaro MO High KA Ertl HC. 2007. Pre-existing AAV capsid-specific CD8 + T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 15: 792–800. [PubMed][CrossRef] · DOI · Paper page
- Wang Z Allen JM Riddell SR Gregorevic P Storb R Tapscott SJ Chamberlain JS Kuhr CS. 2007. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18: 18–26. [PubMed][CrossRef] · DOI · Paper page
- Gao G-P Alvira MR Wang L Calcedo R Johnston J Wilson JM. 2002. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854–11859. [PubMed][CrossRef] · DOI · Paper page
- Li C Narkbunnam N Samulski RJ Asokan A Hu G Jacobson LJ Manco-Johnson MJ Monahan PE Joint Outcome Study Investigators. 2012. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 19: 288–294. [PubMed][CrossRef] · DOI · Paper page
- Carlisle RC Benjamin R Briggs SS Sumner-Jones S McIntosh J Gill D Hyde S Nathwani A Subr V Ulbrich K Seymour LW Fisher KD. 2008. Coating of adeno-associated virus with reactive polymers can ablate virus tropism enable retargeting and provide resistance to neutralising antisera. J Gene Med 10: 400–411. [PubMed][CrossRef] · DOI · Paper page
- Georg-Fries B Biederlack S Wolf J Hausen zur H. 1984. Analysis of proteins helper dependence and seroepidemiology of a new human parvovirus. Virology 134: 64–71. [CrossRef] · DOI · Paper page
- Jacobson EM Huber A Tomer Y. 2008. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J Autoimmun 30: 58–62. [PubMed][CrossRef] · DOI · Paper page
- Taneja V David CS. 2001. Lessons from animal models for human autoimmune diseases. Nat Immunol 2: 781–784. [PubMed][CrossRef] · DOI
- Erles K Sebökovà P Schlehofer JR. 1999. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 59: 406–411. [CrossRef] · DOI · Paper page
- Grewal IS Flavell RA. 1998. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111–135. [PubMed][CrossRef] · DOI · Paper page
- Nathwani AC Gray JT McIntosh J Ng CYC Zhou J Spence Y Cochrane M Gray E Tuddenham EGD Davidoff AM. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109: 1414–1421. [PubMed][CrossRef] · DOI · Paper page
- Chen S Kapturczak M Loiler SA Zolotukhin S Glushakova OY Madsen KM Samulski RJ Hauswirth WW Campbell-Thompson M Berns KI Flotte TR Atkinson MA Tisher CC Agarwal A. 2005. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 16: 235–247. [PubMed][CrossRef] · DOI · Paper page
- Summerford C Bartlett JS Samulski RJ. 1999. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78–82. [PubMed] · DOI · Paper page
- Akache B Grimm D Pandey K Yant SR Xu H Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8 2 3 and 9. J Virol 80: 9831–9836. [PubMed][CrossRef] · DOI · Paper page
- Ling C Lu Y Kalsi JK Jayandharan GR Li B Ma W Cheng B Gee SWY McGoogan KE Govindasamy L Zhong L Agbandje-McKenna M Srivastava A. 2010. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 21: 1741–1747. [PubMed][CrossRef] · DOI · Paper page
- Wu Z Asokan A Grieger JC Govindasamy L Agbandje-McKenna M Samulski RJ. 2006. Single amino acid changes can influence titer heparin binding and tissue tropism in different adeno-associated virus serotypes. J Virol 80: 11393–11397. [PubMed][CrossRef] · DOI · Paper page
- Weller ML Amornphimoltham P Schmidt M Wilson PA Gutkind JS Chiorini JA. 2010. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16: 662–664. [PubMed][CrossRef] · DOI · Paper page
Cited by
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citationGhosh, S., Brown, A. M., Jenkins, C., & Campbell, K. (2020) · Applied Biosafety · doi:10.1177/1535676019899502 · Cited by 218
Prommersberger, S., Reiser, M., Beckmann, J., Danhof, S., Amberger, M., Quade-Lyssy, P., Einsele, H., Hudecek, M., Bonig, H., & Ivics, Z. (2021) · Gene Therapy · doi:10.1038/s41434-021-00254-w · Cited by 182
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
High-efficiency nonviral CRISPR/Cas9-mediated gene editing of human T cells using plasmid donor DNA
Oh, S. A., Senger, K., Madireddi, S., Akhmetzyanova, I., Ishizuka, I. E., Tarighat, S., Lo, J. H., Shaw, D., Haley, B., & Rutz, S. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211530 · Cited by 88
Metadata
- Authors
- Salganik, M., Hirsch, M. L., & Samulski, R. J.
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2015-07-02
- Volume
- 3
- Issue
- 4
- ISSN
- 2165-0497 (ISSN-L)
- OpenAlex
- W876571388
- Cited by
- 87
- References
- 86
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.